VIVUS (VVUS) Says Qsymia Now Covered by Express Scripts' (ESRX)

December 20, 2012 6:31 AM EST
VIVUS, Inc. (NASDAQ: VVUS) today announced that Express Scripts (Nasdaq: ESRX), among the country's largest Pharmacy Benefit Managers (PBMs), has added Qsymia™ to its national pharmacy formularies, allowing for coverage where available by benefit design of the first new FDA-approved medication commercially available in the U.S. in over a decade for the treatment of chronic weight management.

Express Scripts provides the formulary design, pharmaceutical contract management and claims processing for some of the largest payers and employers in the U.S.

Qsymia has been added as a standard benefit option to Express Scripts' national formulary in a tier-3 position with a prior authorization. Under the Express Scripts plan, participating patients will now pay an estimated $50.00 to $60.00 for their co-payment for a monthly prescription of Qsymia, approximately one-third of the retail price.

Qsymia is available only through mail order from the Qsymia Certified Home Delivery Pharmacy Network, including CVS Pharmacy, Express Scripts, Walgreens and Walmart, as part of the Qsymia Risk Evaluation and Mitigation Strategy (REMS) program.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment